These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35887049)

  • 21. In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing.
    Abdelkader A; Elzemrany AA; El-Nadi M; Elsabbagh SA; Shehata MA; Eldehna WM; El-Hadidi M; Ibrahim TM
    Virology; 2022 Aug; 573():96-110. PubMed ID: 35738174
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.
    Ahmad S; Waheed Y; Ismail S; Bhatti S; Abbasi SW; Muhammad K
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33800013
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling.
    Pitsillou E; Liang J; Hung A; Karagiannis TC
    J Mol Graph Model; 2022 Jul; 114():108193. PubMed ID: 35462185
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach.
    Romeo I; Ambrosio FA; Costa G; Corona A; Alkhatib M; Salpini R; Lemme S; Vergni D; Svicher V; Santoro MM; Tramontano E; Ceccherini-Silberstein F; Artese A; Alcaro S
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364347
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
    Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
    Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by
    Bhowmick S; Mistri TK; Khan MR; Patil PC; Busquets R; Ashif Ikbal AM; Choudhury A; Roy DK; Palit P; Saha A
    J Biomol Struct Dyn; 2024 Sep; 42(14):7107-7127. PubMed ID: 37482789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase.
    White MA; Lin W; Cheng X
    J Phys Chem Lett; 2020 Nov; 11(21):9144-9151. PubMed ID: 33052685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
    Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
    Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study.
    Patel S; Hasan H; Umraliya D; Sanapalli BKR; Yele V
    J Mol Model; 2023 May; 29(6):176. PubMed ID: 37171714
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug repositioning against COVID-19: a first line treatment.
    Bibi N; Farid A; Gul S; Ali J; Amin F; Kalathiya U; Hupp T
    J Biomol Struct Dyn; 2022; 40(23):12812-12826. PubMed ID: 34519259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of new drug indications for COVID-19: A drug repurposing approach.
    Kumari P; Pradhan B; Koromina M; Patrinos GP; Steen KV
    PLoS One; 2022; 17(5):e0267095. PubMed ID: 35609015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico drug repurposing carvedilol and its metabolites against SARS-CoV-2 infection using molecular docking and molecular dynamic simulation approaches.
    Zhang C; Liu J; Sui Y; Liu S; Yang M
    Sci Rep; 2023 Dec; 13(1):21404. PubMed ID: 38049492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J).
    Kalamatianos KG
    Mol Divers; 2023 Jun; 27(3):1087-1099. PubMed ID: 35739375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective.
    Chakraborty A; Ghosh R; Soumya Mohapatra S; Barik S; Biswas A; Chowdhuri S
    Gene; 2024 Sep; 922():148553. PubMed ID: 38734190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach.
    Gangadharan S; Ambrose JM; Rajajagadeesan A; Kullappan M; Patil S; Gandhamaneni SH; Veeraraghavan VP; Nakkella AK; Agarwal A; Jayaraman S; Surapaneni KM
    J Infect Public Health; 2022 Nov; 15(11):1180-1191. PubMed ID: 36240528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an
    Ambrosio FA; Costa G; Romeo I; Esposito F; Alkhatib M; Salpini R; Svicher V; Corona A; Malune P; Tramontano E; Ceccherini-Silberstein F; Alcaro S; Artese A
    J Chem Inf Model; 2023 Jun; 63(11):3601-3613. PubMed ID: 37227780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.